Arch Therapeutics (ARTH) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Arch Therapeutics (OTCMKTS:ARTH) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “

Get Arch Therapeutics alerts:

Several other equities analysts have also recently issued reports on the stock. Roth Capital restated a buy rating on shares of Arch Therapeutics in a research note on Tuesday, February 5th. Ifs Securities upgraded shares of Arch Therapeutics from an outperform rating to a strong-buy rating in a research note on Friday, February 1st. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $1.75.

ARTH opened at $0.38 on Friday. Arch Therapeutics has a 52-week low of $0.26 and a 52-week high of $0.69.

About Arch Therapeutics

Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.

Featured Story: What is the downside to momentum investing?

Get a free copy of the Zacks research report on Arch Therapeutics (ARTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com